London-based KGK Synergize Inc., a contract research organization offering human clinical trials to the health nutrition industry, is launching a new site in Orlando, FL.
This new site allows KGK to offer faster recruitment timelines while delivering the same quality and efficiency that its Canadian site offers, and the new site will broaden the KGK patient database to Orlando’s population of 2.1 million, reported the company.
“The launch of our US site is a step in the right direction,” said Najla Guthrie, president and CEO, KGK Synergize Inc. “Our clients are looking for a partner who can complete their clinical trial in a timely and efficient approach. This new site will allow us to reach a larger population and in turn offer our clients the faster recruitment timelines they have been looking for.”
KGK Synergize Inc. has partnered with Alan Novotny, former CEO of TissueNet, to oversee the KGK US site. Novotny has over 20 years experience starting, building and managing multifaceted technology companies in biotech and health care related industries, according to the company.
“I am thrilled about the opening of KGK US.,” said Alan Novotny, CEO of the U.S. site. “At KGK US, our clients can expect timelines and efficiency that is unmatched regarding clinical trials. This new site will help establish KGK as a worldwide leader in clinical trial research. We will deliver you the confidence and expertise you would expect from your partner in clinical research.”
For more information, visit www.kgksynergize.com.
